New Analogues to Acyclovir with Increased Potency to Herpes Viruses

  • A. Paul Fiddian
Part of the Applied Virology Research book series (AOTP, volume 1)


Acyclovir is highly active in vitro against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2, respectively), moderately active against varicella-zoster virus (VZV) and Eps-tein-Barr virus (EBV), and relatively inactive against cytomegalovirus (CMV). The full extent of the clinical value of acyclovir is still being defined, but we already know much about its efficacy and tolerance in a wide range of herpes virus infections. This has previously been discussed in a number of reviews, including Fiddian (1984), Fiddian et al. (1984), Rees and Fiddian (1985), and most recently Fiddian and Grant (1985).


Herpes Simplex Virus Herpes Zoster Herpes Simplex Virus Infection Oral Acyclovir Intravenous Acyclovir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allaudeen, H. S., Descamps, J., and Sehgal, R. K. (1982). Antiviral Res. 2, 123–133.PubMedCrossRefGoogle Scholar
  2. Andersson, J., Britton, S., Ernberg, I., Andersson, U., Henle, W., Sköldenberg, B., and Tisell, A. (1986). J. Infect. Dis. 153, 283–290.PubMedCrossRefGoogle Scholar
  3. Bach, M. C., Bagwell, S. P., Knapp, N. P., Davis, K. M., and Hedstrom, P. S. (1985). Ann. Intern. Med. 103, 381–382.PubMedCrossRefGoogle Scholar
  4. Balfour, H. H., Jr. (1986). In Clinical Advances in Antiviral Therapy (P. Lietman, S. Ohtani, and A. P. Fiddian, eds.), pp. 27–33, University of Tokyo Press, Tokyo, Japan.Google Scholar
  5. Balfour, H. H., Jr., Bean, B., Mitchell, C. D., Sachs, G. W., Boen, J. R., and Edelman, C. K. (1982). Am. J. Med. 73(1a), 241–248.PubMedCrossRefGoogle Scholar
  6. Balfour, H. H., Jr., Bean, B., Laskin, O. L., Ambinder, R. F., Meyers, J. D., Wade, J. C., Zaia, J. A., Aeppli, D., Kirk, L. E., Segreti, A. C., and Keeney, R. E. (1983). N. Engl. J. Med. 308, 1448–1453.PubMedCrossRefGoogle Scholar
  7. Colby, B. M., Shaw, J. E., Elion, G. B., and Pagano, J. S. (1980). J. Virol. 34, 560–568.PubMedGoogle Scholar
  8. Colby, B. M., Furman, P. A., Shaw, J. E., Elion, G. B., and Pagano, J. S. (1981). J. Virol. 38, 606–611.PubMedGoogle Scholar
  9. Collins, P., and Oliver, N. M. (1985). Antiviral Res. 5, 145–156.PubMedCrossRefGoogle Scholar
  10. Felsenstein, D., D’Amico, D. J., Hirsch, M. S., Neumeyer, D. A., Cederberg, D. M., De Miranda, P., and Schooley, R. T. (1985). Ann. Intern. Med. 103, 377–380.PubMedCrossRefGoogle Scholar
  11. Fiddian, A. P. (1984). In Applied Virology (E. Kurstak, ed.), pp. 103–120, Academic, Orlando, Florida.CrossRefGoogle Scholar
  12. Fiddian, A. P., and Grant, D. M. (1985). Abs. Hyg. Commun. Dis. 60, R1–R22.Google Scholar
  13. Fiddian, A. P., Brigden, D., Yeo, J. M., and Hickmott, E. (1984). Antiviral Res. 4, 99–117.PubMedCrossRefGoogle Scholar
  14. Gluckman, E., Lotsberg, J., Devergie, A., Zhao, X. M., Melo, R., Gomez-Morales, M., Nebout, T., Mazeron, M. C., and Perol, Y. (1983). Lancet 2, 706–708.PubMedCrossRefGoogle Scholar
  15. Hann, I. M., Prentice, H. G., Blacklock, H. A., Ross, M. G. R., Brigden, D., Rosling, A. E., Burke, C., Crawford, D. H., Brumfitt, W., and Hoffbrand, A. V. (1983). Br. Med. J. 2, 384–388.CrossRefGoogle Scholar
  16. King, D. H., and Fiddian, A. P. (1986). In Clinical Advances in Antiviral Therapy (P. Lietman, S. Ohtani, and A. P. Fiddian, eds.), pp. 65–71, University of Tokyo Press, Tokyo, Japan.Google Scholar
  17. Krenitsky, T. A., Hall, W. W., De Miranda, P., Beauchamp, L. M., Schaeffer, H. J., and Whiteman, P. D. (1984). Proc. Natl. Acad. Sci. USA 81, 3209–3213.PubMedCrossRefGoogle Scholar
  18. Lin, J-C., Smith, M. C., and Pagano, J. S. (1984). J. Virol. 50, 50–55.PubMedGoogle Scholar
  19. Lundgren, G., Wilczek, H., Lönnqvist, B., Lindholm, A., Wahren, B., and Ringden, O. (1985). Scand. J. Infect. Dis. (Suppl) 47, 137–144.Google Scholar
  20. McGill, J., MacDonald, D. R., Fall, C., McKendrick, G. D. W., and Copplestone, A. (1983). J. Infect. Dis. 6, 157–161.Google Scholar
  21. McKendrick, M. W. (1985). Scand. J. Infect. Dis. (Suppl) 47, 76–79.Google Scholar
  22. McKendrick, M. W., Care, C., Burke, C., Hickmott, E., and McKendrick, G. D. W. (1984). J. Antimicrob. Chemother. 14, 661–665.PubMedCrossRefGoogle Scholar
  23. Masur, H., Lane, C., Palestine, A., Smith, P. D., Manischewitz, J., Stevens, G., Fujikawa, L., Macher, A. M., Nussenblatt, R., Baird, B., McGill, M., Wittek, A., Quinnan, G. V., Parrillo, J. E., Rook, A. H., Eron, L. J., Poretz, D. M., Goldenberg, R. I., Fauci, A. S., and Gelmann, E. P. (1986). Ann. Intern. Med. 104, 41–44.PubMedCrossRefGoogle Scholar
  24. Meyers, J. D. (1985). Scand. J. Infect. Dis. (Suppl.) 47, 128–136.Google Scholar
  25. Nicholson, K. G. (1984). Lancet 2, 617–621.PubMedCrossRefGoogle Scholar
  26. Novelli, V. M., Marshall, W. C., Yeo, J., and McKendrick, G. D. (1984). J. Infect. Dis. 149, 478.PubMedCrossRefGoogle Scholar
  27. Pagano, J. S., and Datta, A. K. (1982). Am. J. Med. 73(1A), 18–26.PubMedCrossRefGoogle Scholar
  28. Pagano, J. S., Sixbey, J. W., and Lin, J.-C. (1983). J. Antimicrob. Chemother. 12(B), 113–121.CrossRefGoogle Scholar
  29. Peterslund, N. A., Seyer-Hansen, K., Ipsen, J., Esmann, V., Schonheyder, H., and Juhl, H. (1981). Lancet 2, 827–830.PubMedCrossRefGoogle Scholar
  30. Prober, C. G., Kirk, L. E., and Keeney, R. E. (1982). J. Pediatr. 101, 622–625.PubMedCrossRefGoogle Scholar
  31. Rees, P. J., and Fiddian, A. P. (1985). J. Drug Ther. Res. 10, 637–640.Google Scholar
  32. Saral, R., Burns, W. H., Laskin, O. L., Santos, G. W., and Lietman, P. S. (1981). N. Engl. J. Med. 305, 63–67.PubMedCrossRefGoogle Scholar
  33. Selby, P., Powles, R. L., Blake, S., Stolle, K., Mbidde, E. K., McElwain, T. J., Hickmott, E., Whiteman, P. D., and Fiddian, A. P. (1984a). Lancet 2, 1428–1430.PubMedCrossRefGoogle Scholar
  34. Selby, P., Powles, R., Stolle, K., and Stern, H. (1984b). Br. Med. J. 2, 253.CrossRefGoogle Scholar
  35. Shepp, D. H., Dandliker, P. S., De Miranda, P., Burnette, T. C., Cederberg, D. M., Kirk, L. E., and Meyers, J. D. (1985). Ann. Intern. Med. 103, 368–373.PubMedCrossRefGoogle Scholar
  36. Shepp, D. H., Dandliker, P. S., and Meyers, J. D. (1986). N. Engl. J. Med. 314, 208–212.PubMedCrossRefGoogle Scholar
  37. Whiteman, P. D., Bye, A., Fowle, A. S. E., Jeal, S., Land, G., and Posner, J. (1984). Eur. J. Clin. Pharmacol. 27, 471–475.PubMedCrossRefGoogle Scholar
  38. Whitley, R. J., Alford, C. A., Hirsch, M. S., Schooley, R. T., Luby, J. P., Aoki, F. Y., Hanley, D., Nahmias, A. J., and Soong, S.-J. (1986). N. Engl. J. Med. 314, 144–149.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • A. Paul Fiddian
    • 1
  1. 1.Clinical Antiviral Therapy SectionWellcome Research LaboratoriesBeckenham, KentEngland

Personalised recommendations